---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-027445"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-07-02T20:23:41+00:00"
generated_at: "2026-07-02T20:25:07.166137+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio raises $1B in convertible preferred equity from Sixth Street and KKR

## Summary
- Sixth Street invested $800M and HCRx (KKR affiliate) invested $133.9M in Series A convertible preferred stock.
- Initial conversion price of $137.79 per share (over 100% premium to 30-day VWAP); increases to $153.10 after year 5.
- Preferred stock carries 7.00% annual dividend, payable in kind or cash at Company's option; no scheduled maturity.
- Proceeds to accelerate launches of Attruby, BBP-418, encaleret, and infigratinib over next 12 months.
- Company may redeem after year 3 at escalating premiums; conversion mandatory if stock price exceeds 200% of conversion price.

## SEC filing metadata
- accession: 0001140361-26-027445
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-07-02T20:23:41+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/0001140361-26-027445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/ef20077282_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-027445
- JSON: https://secwatch.observer/filing/0001140361-26-027445.json
- Plain text: https://secwatch.observer/filing/0001140361-26-027445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.